Loading...
XHKG
1061
Market cap323mUSD
May 09, Last price  
4.44HKD
1D
2.54%
1Q
70.77%
Jan 2017
33.33%
Name

Essex Bio-Technology Ltd

Chart & Performance

D1W1MN
No data to show
P/E
8.19
P/S
1.51
EPS
0.54
Div Yield, %
3.72%
Shrs. gr., 5y
-0.73%
Rev. gr., 5y
5.47%
Revenues
1.67b
-2.15%
49,197,29182,789,684152,674,582214,070,523116,688,187146,281,574212,716,340267,255,167347,046,987518,299,695654,010,499775,662,998899,589,7291,176,457,9311,279,478,212978,111,1261,637,659,4311,317,710,6161,706,556,1411,669,816,770
Net income
307m
+11.61%
15,547,7533,763,27711,001,92621,826,71011,550,88926,584,37233,202,62838,995,13654,896,69675,273,091104,895,190136,284,381167,298,653231,091,674302,502,420218,925,555345,968,083225,411,310275,259,617307,221,818
CFO
368m
+8.63%
-2,224,8804,403,899-5,786,1943,746,69746,631,16328,123,45223,380,40935,788,51765,119,10334,922,49168,640,46585,278,686193,720,031200,872,681232,858,075299,238,146409,161,400382,785,659339,205,269368,470,081
Dividend
Sep 09, 20240.06 HKD/sh
Earnings
May 28, 2025

Profile

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.
URL
http://www.essexbio.com/
IPO date
Jun 27, 2001
Employees
1,462
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,669,817
-2.15%
1,706,556
29.51%
1,317,711
-19.54%
Cost of revenue
1,349,097
1,435,371
1,066,079
Unusual Expense (Income)
NOPBT
320,720
271,185
251,632
NOPBT Margin
19.21%
15.89%
19.10%
Operating Taxes
68,278
70,755
34,931
Tax Rate
21.29%
26.09%
13.88%
NOPAT
252,441
200,430
216,701
Net income
307,222
11.61%
275,260
22.11%
225,411
-34.85%
Dividends
(59,583)
(39,921)
(54,526)
Dividend yield
Proceeds from repurchase of equity
(1,132)
(12,593)
(14,790)
BB yield
Debt
Debt current
73,064
237,561
107,613
Long-term debt
135,666
78,562
384,689
Deferred revenue
382,121
Other long-term liabilities
36,372
(382,121)
Net debt
(398,983)
(239,265)
(79,094)
Cash flow
Cash from operating activities
368,470
339,205
382,786
CAPEX
(44,397)
(21,031)
(282,913)
Cash from investing activities
(106,591)
(54,338)
(302,030)
Cash from financing activities
(200,813)
(309,925)
(169,110)
FCF
387,319
115,777
306,422
Balance
Cash
560,739
515,025
543,492
Long term investments
46,973
40,363
27,904
Excess cash
524,221
470,060
505,510
Stockholders' equity
2,050,442
1,850,498
1,677,230
Invested Capital
1,822,910
1,747,739
1,678,613
ROIC
14.14%
11.70%
13.27%
ROCE
13.66%
12.03%
11.32%
EV
Common stock shares outstanding
582,320
595,646
599,388
Price
Market cap
EV
EBITDA
376,592
331,061
293,545
EV/EBITDA
Interest
11,212
11,472
Interest/NOPBT
4.13%
4.56%